The deal with Elbion focuses on discovering drugs to treat schizophrenia, while collaborations with Nautilus Biotech and MediVas are aimed at developing more advanced haemophilia treatments, either by developing new drugs or a better drug delivery system.
Wednesday, February 7, 2007
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment